New cancer pill doubles survival time in trial

Hinzugefügt: 2026-06-03

[00:00:00]A major breakthrough could be giving new hope to people battling one of the deadliest forms of cancer. Researchers say an experimental pill for advanced pancreatic cancer nearly doubled survival time in a major clinical trial.

[00:00:13]Patients taking the drug called Rexin Rasib lived a median of 13 months compared to nearly 7 months for those receiving more chemotherapy. Doctors say the treatment targets a genetic mutation found in more than 90% of pancreatic cancer cases, a target scientists spent decades trying to crack. Even more encouraging, patients reported less pain, better quality of life, and fewer severe side effects than traditional chemotherapy. Experts are calling the results a potential game-changer with some saying the drug could become a new standard of care if approved by the FDA.

[00:00:47]Pancreatic cancer remains one of the toughest cancers to treat, but researchers say this could mark a turning point in the fight against this disease.